Partnership between WC Pharmaceticals and WraSer Pharmaceuticals

For Immediate Release
 
Women’s Choice Pharmaceuticals Announces the Co-Promotion Agreement for Trezix® Oral Capsules(Acetaminophen 356.4mg/Caffeine 30 mg/Dihydrocodeine 16 mg)
 
Gilbert, AZ – July 15, 2011 – Gilbert-based Women’s Choice Pharmaceuticals (WC Pharma) announced today it has entered into a co-promotion agreement with Wraser Pharmaceuticals to market Trezix® Oral Capsules to obstetricians, gynecologist and urologists.
 
Trezix® Oral Capsules received FDA approval in April 2007 and combines Acetaminophen and Caffeine with the narcotic analgesic Dihydrocodeine, representing a safe and effective therapy for the treatment of moderate to moderately severe pain. Physicians have few alternatives in prescribing a combination of Caffeine with a narcotic analgesic, and Trezix® fills this important void in the market for effective pain-management treatments.
 
 “We are extremely excited to enter into this co-promotion agreement,” said Joe Ducharme, President of WC Pharma. “Trezix® fills an important niche in the pain market and offers a nice option to the physicians we target. Our analysis indicates that the OB/GYNs are frequent prescribers of combination pain products, which we believe makes Trezix® Capsules a good fit for our product portfolio.”
 
“WraSer Pharmaceuticals is excited to work with WC Pharma in building a broader brand identity of the Trezix® brand.” “WC Pharma also offers WraSer Pharmaceuticals a larger opportunity to expand the product availability into large metropolitan markets and specialized markets across the US,” said Tom Hann, Direct of Business Development. Trezix® is available immediately through wholesale and retail pharmacies by prescription only.
 
About Women’s Choice Pharmaceuticals, LLC
Women's Choice Pharmaceuticals is an innovative specialty pharmaceutical company whose primary focus is to provide high quality prescription products to healthcare providers in the United States. The company provides technology based prescription products to the women's health market place, with their primary product portfolio consisting of three patent protected products with market caps exceeding $500 million. Their nationwide sales force will target OB/GYNS and selected other medical specialties. (www.wcpharma.com).   
 
About WraSer Pharmaceuticals, LLC
Wraser is a privately held specialty pharmaceutical company headquartered in Ridgeland, MS. The company actively markets prescription pharmaceuticals products focused on primary care, pediatric and specialty markets. WraSer markets its products through its proprietary sales force. The company is continually expanding its product portfolio through direct development, FDA submission, partnerships and in-licensing/out-licensing agreements. Further information regarding WraSer is available at (www.wraser.com). 
 
Trezix is a registered trademark of WraSer, LLC.
 


Posted on 7/15/2011

View All Postings